Tumor tissues from CDK4/6i monotherapy showed higher protein levels of LRPPRC and CDK6 compared to the control group, indicating the activation of the LRPPRC-CDK6 feedback loop after CDK4/6i treatment in vivo. This evidence concerns the gene CDK6 and neoplasm.